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Abstract
Background Higher-level gait disorder (HLGD) in older
adults is characterized by postural instability, stepping
dysrhythmicity, recurrent falls and progressive immobility.
Cognitive impairments are frequently associated with
HLGD.
Objectives The aim of this study was to compare gait and
cognitive performance before and after the use of riv-
astigmine in patients with HLGD, free from cognitive
impairment or Parkinsonism.
Methods Fifteen non-demented patients with HLGD (age
79.2 ± 5.9 years; 11 women; Mini-Mental State
Examination [MMSE] 28.3 ± 1.4) received escalating
doses of rivastigmine for 12 weeks in an open-label, pilot
study. They were assessed before and after treatment (week
0 and week 12), and after a 4-week washout period (week
16). Assessments included the Mindstreams computerized
neuropsychological battery, Activities-speciﬁc Balance
Conﬁdence Scale, State-Trait Anxiety Inventory, Geriatric
Depression Scale, Timed Up and Go (TUG) test, gait speed
and stride time variability. One-way multiple analysis of
variance tests for repeated measures were used, and Pillai’s
trace test was considered as robust to investigate signiﬁcant
differences.
Results The mean dose of rivastigmine during the
8–12 week period was 5.1 ± 2.3 mg/day. A positive effect
was observed on the Mindstreams memory subscale and
anxiety scores [Pillai’s trace: F(6,724) = 0.508, p = 0.010;
and F(7,792) = 0.545, p = 0.006, respectively, over the
course of the study] as well as on mobility (TUG test) [Pil-
lai’s trace: F(4,863) = 0.448; p = 0.028], whereas gait
speed and stride time variability did not change.
Conclusions The use of relatively low-dose rivastigmine
did not affect gait speed and stride time variability; how-
ever, the general mobility and anxiety were improved.
These preliminary results warrant a larger, randomized,
placebo-controlled study.
1 Introduction
Higher-level gait disorder (HLGD) is a progressive multi-
factorial disorder in elderly adults, characterized by slow
gait, stepping dysrhythmicity, postural instability, recurrent
falls, progressive immobility, wheelchair use and institu-
tionalization [1–5]. The pathophysiology of gait and bal-
ance impairment in people with HLGD is poorly
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pyramidal, extrapyramidal, cerebellar, autonomic or
peripheral disturbances [2].
Cognitive functions play an important role in the regu-
lation of walking, particularly in older adults where deﬁcits
in executive functions and attention are independently
associated with postural instability, impairments in daily
living activities, and falls [6, 7]. In support of this idea,
acetylcholinesterase inhibitors, cognitive enhancer medi-
cations for symptomatic treatment of patients with Alz-
heimer’s and Parkinson’s diseases, were found to reduce
gait variability [8], and increase gait velocity [9, 10], in
patients with Alzheimer’s disease [9, 10], and to reduce fall
risks in patients with Alzheimer’s disease and in non-
demented patients with Parkinson’s disease [9, 10].
Two additional, randomized controlled, double-blind
trials examining the effect of cholinesterase inhibitors on
gait in a larger cohort of individuals with mild cognitive
impairment [11] and in non-demented patients with Par-
kinson’s disease are currently recruiting patients [12]. The
aim of this study was to evaluate the effect of rivastigmine,
an inhibitor of both butyrylcholinesterase and acetylcho-
linesterase, on locomotion and cognitive functions in
elderly patients with HLGD who are free from cognitive or
other motor impairments in an open-label, pilot exploratory
study. Cholinergic agents affect many aspects of cognition,
which suggests that the primary effect may be on an
attention or executive system with a secondary modulating
inﬂuence on memory, language, and visuospatial skills;
improvement in attention may further reduce apathy.
Cholinesterase inhibitors may play an important role in
controlling neuropsychiatric and behavioral disturbances in
patients, i.e. depression, anxiety, disinhibition and agitation
[13]. The midbrain mesencephalic locomotor region
(MLR), comprising the pedunculopontine (PPN) and
cuneiform nuclei (CN) [14], has recently been highlighted
as an important region with respect to gait and balance
disorders [15, 16].
On the basis of these data, together with the fact that
speciﬁc lesions of the cholinergic PPN neurons in monkeys
induce gait and postural deﬁcits [17], we hypothesized that
cholinergic deﬁcit may contribute to the gait and balance
disorders presented by HLGD patients, and that cholines-




Twenty consecutive consenting patients with HLGD (14
women, age range 69–89 years, mean 79.6 ± 6.1 years)
who attended our Movement Disorders Unit were origi-
nally enrolled in this pre-post intervention study. These
patients were diagnosed as having HLGD by three move-
ment disorders specialists (NG, TG and DM) using criteria
described previously [2]. Any other causes for their gait
difﬁculties were excluded in the clinical evaluation. All 20
subjects were able to walk independently for at least 30 m.
Those who were on a stable dose of other medications for
at least 1 month prior to the baseline assessment agreed not
to change their medications during the 16 weeks of the
current study. Patients diagnosed as having dementia
according to Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM–IV) criteria and Mini-Mental
State Examination (MMSE) scores less than 26 were
excluded, as were those with clinically signiﬁcant depres-
sion, orthopedic problems and any other neurological
abnormalities that could have had an effect on gait and
postural responses. Patients with a history of severe head
trauma or stroke and those with signiﬁcant structural brain
lesions on computerized tomography or with clinically
signiﬁcant orthostatic hypotension were also excluded. In
addition, we excluded patients with active malignancy,
uncontrolled symptomatic heart disease, diabetes mellitus
or hypertension, as well as those with psychiatric disorders.
All of the enrolled patients had normal vitamin B12, folic
acid, as well as general hematology, electrolytes, renal and
liver function tests, and a negative venereal disease
research laboratory (VDRL) test. The study was approved
by the Ethics Committee of the Tel Aviv Medical Center,
and each patient signed an informed consent form prior to
enrolling in the study.
2.2 Drug Escalation
Rivastigmine was given orally at an initial dose of 1.5 mg
twice daily. This dose was increased to 3 mg twice daily
after 4 weeks, and to 4.5 mg twice daily after 8 weeks.
Patients who developed side effects at any stage were
either left on the same dose for 2 or more weeks or had
their daily dose reduced to the previous level. We tried to
keep the dose of rivastigmine constant at the maximal
tolerated dose between week 8 and week 12 of the trial, the
point at which administration of the drug was stopped.
2.3 Clinical Evaluations
The patients were assessed at baseline (week 0), shortly
after the termination of rivastigmine medication (week 12),
and after a 4-week washout period (week 16). Each
assessment included evaluation of the subject’s general
condition together with registration of vital functions and
side effects. Also included were the scores of the MMSE
[18], the short form of the Geriatric Depression Scale
58 T. Gurevich et al.(GDS) [19], the Activities-speciﬁc Balance Conﬁdence
scale (ABC) for measuring the level of fear of falling [20],
and the State-Trait Anxiety Inventory (STAI) [21]. Cog-
nitive performance was assessed using Mindstreams, a
computerized neuropsychological battery, which includes
tests for the domains of memory, attention, executive,
visual-spatial functions and global cognitive function [22].
All cognitive scores in Mindstreams are normalized, where
100 is the mean and one SD is 15 points for matched age
and education levels (we therefore used cutoff scores\85
to denote impairment).
2.4 Gait Assessment
The Timed Up and Go (TUG) test [23] was administered
for a general assessment of balance, mobility, lower
extremity function, and fall risk [24, 25]. A computerized
force-sensitive system was used to quantify gait and stride-
to-stride variability [26]. The system measures the forces
underneath the foot as a function of time and consists of a
pair of insoles (footswitch) and a recording unit. Each
insole contains four load sensors that cover the surface of
the sole and measure the normal (vertical) forces under the
foot. A small recording unit (11.5 9 6.5 9 3.5 cm; 0.5 kg)
is carried on the subject’s waist. Plantar pressures under
each foot are recorded at a rate of 100 Hz. Measurements
are stored in a memory card during the walk, after which
they are transferred to a personal computer for further
analysis. Average stride time and stride time variability
were determined from the recorded force using previously
described methods [27, 28]. Variability measures were
quantiﬁed by means of the coefﬁcient of variation, e.g.
stride-time variability = 100 9 (average stride time/stan-
dard deviation).
2.5 Statistics
The descriptive step included a calculation of mean and
standard deviation. All numeric variables were analyzed
using repeated measures. One-way multiple analysis of
variance (MANOVA) was used to compare the three
assessments on weeks 0, 12, and 16. In all cases, the post
hoc Pillai’s trace test was considered as robust to investi-
gate signiﬁcant differences. The results were evaluated in a
conﬁdence interval range of 95 % and a signiﬁcance level
of p\0.05. Statistical analysis was performed using SPSS
statistical software (SPSS, Chicago, IL, USA).
3 Results
The 20 enrolled patients had suffered from gait disorders
for 3.9 ± 3.6 years before enrolling in the study. Three
patients dropped out at weeks 3–4 into the study due to
general weakness, fatigue, insomnia and/or non-compli-
ance while on a dose of 1.5 mg twice daily. Two patients
stopped escalation of rivastigmine at 3–4 weeks, while on a
stable dose of 3.0 mg, because of dizziness, vertigo, nau-
sea, blurred vision, diarrhea, general weakness and/or
fatigue, which completely disappeared following dose
lowering. Fifteen patients (mean age 79.2 ± 5.9 years,
range 72–89 years, 11 women) completed the study. The
mean rivastigmine dose at study closure (week 12) was
5.1 ± 2.3 mg (range 3.0–9.0 mg). The effects of rivastig-
mine on mental functions, affect and gait are presented in
Table 1.
The mean Mindstreams memory subscale scores con-
sistently improved, from 85.7 ± 9.6 at baseline to
88.97 ± 6.6 at week 12, and further to 93.9 ± 13.1 at
week 16 [Pillai’s trace F(6,724) = 0.508; p = 0.010]. The
size effect of rivastigmine on the memory subscale was
considerable, exceeding 10 points, in 12 patients (80 %).
The mean anxiety scores according to the STAI scale
improved from 37.5 ± 7.6 points at baseline to 34.3 ± 8.1
points at the end of the medication period (week 12),
returning to 38.5 ± 10 points after washout (week 16)
[Pillai’s trace F(7,792) = 0.545; p = 0.006].
Locomotion and mobility signiﬁcantly improved
according to the TUG test, changing from 14.1 ± 3.8 s at
baseline to 13.1 ± 2.4 s at week 12 and 13.5 ± 2.5 s at
week 16, indicating a signiﬁcant beneﬁcial drug effect
[Pillai’s trace F(4,863) = 0.448; p = 0.028]. In contrast,
rivastigmine treatment had no effect on MMSE, ABC and
GDS scores, and other (non-memory) Mindstreams
domains, as well as on gait speed and stride-time vari-
ability (Table 1).
4 Discussion
HLGD is a disease of old age resulting in restriction of
mobility and often accompanied by cognitive decline [29].
The association between cognitive decline and mobility
impairments in the elderly is now well established [30],
and abnormal gait itself is an early marker for future
cognitive decline [31]. The present pilot study was an
open-labeled exploratory trial that suggested a possible
positive rivastigmine effect on cognitive and motor func-
tion. The beneﬁts of rivastigmine, if conﬁrmed in future
studies, can be attributed to its effect on affect (anxiety)
and/or cognition (executive functions). Decrease of the
anxiety level with rivastigmine treatment has also been
reported in patients with Alzheimer’s disease [32].
Rivastigmine’s treatment association with shortening of
the TUG test may be indicative of improved mobility,
stability, and decrease in fall risk in patients with HLGD.
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walking and turning, and is inﬂuenced by walking speed,
muscle strength and balance [33, 34]. The TUG test is a
sensitive and speciﬁc measure for identifying community-
dwelling adults who are at risk for falls [35]. Time to
completion above 14 s indicates a high risk of falls in the
elderly population [25, 36].
Timing of the TUG test also reﬂects cognitive abilities,
given its independent association with better performance
on global cognition, memory tests and faster processing
speed in community-dwelling adults older than 50 years of
age [37]. Earlier studies reported that rivastigmine had
signiﬁcantly improved executive function on tests for
ﬂexibility of thinking, problem solving and planning in
patients with parkinsonian dementia [38, 39]. Our results
have not demonstrated an effect on executive functions,
probably because of a ceiling effect. The same explanation
probably applies to the lack of effect on MMSE, attention
and visuospatial skills. These ﬁndings support the
hypothesis that rivastigmine may affect frontal subcortical
circuits in parkinsonian patients [39], although we did not
observe any improvement of executive functions in the
present study. The limited effect of rivastigmine on gait
that had been observed in the present study may have been
caused by the comparatively low doses of the medicament.
Nevertheless, it was accompanied by considerable adverse
effects. Advanced patch delivery transdermal systems
containing larger doses of rivastigmine may be more
effective because of the stable rivastigmine plasma levels
and better tolerability [40].
Limitations of this study include the small number of
participants, making the power of this study low, and its
open-label design (allowing training or a placebo effect on
mobility as well as on anxiety).
Although we did not employ a blinded evaluator, it
ought to be outlined that the present study included mainly
the Mindstreams computerized tests as an endpoint, and
that the target kinematic measures were generated auto-
matically. Placebo-controlled studies with larger doses of
rivastigmine are needed to determine the possibility of
further improvements of locomotion and better perfor-
mance of activities of daily living in elderly individuals
with HLGD.
5 Conclusions
The ﬁndings of this exploratory, small, open-label study
indicate a possible positive effect of rivastigmine on anx-
iety and mobility in patients with HLGD. The possibility
that the drug will have the capability to prevent falls and
maintain independent mobility justiﬁes a large-scale, pla-
cebo-controlled clinical trial with a calculation of a theo-
retical number needed to show a result in advance.
Table 1 Effects of rivastigmine on cognitive characteristics and gait parameters in 15 patients with higher-level gait disorder
Baseline, week 0
(n = 15)
After treatment, week 12
(n = 15)
Washout after treatment, week 16
(n = 15)
Pillai’s trace test
Mean rivastigmine dose (mg/
day)
0 5.1 ± 2.3 0
MMSE 28.3 ± 1.4 28.13 ± 1.1 28.4 ± 1.4 NS
Mindstreams global
cognitive score
90.43 ± 7.1 91.52 ± 7.5 93.47 ± 9.8 NS
Memory subscale 85.75 ± 9.6 88.97 ± 6.6 93.98 ± 13.1 F(6,724) = 0.508;
a
p = 0.010
Anxiety subscale 37.46 ± 7.6 34.26 ± 8.1 38.53 ± 10.0 NS
Executive function subscale 90.10 ± 8.5 90.56 ± 8.4 92.72 ± 8.7 NS
Visuospatial subscale 86.49 ± 11.0 86.99 ± 15.8 86.6 ± 12.7 NS
Attention subscale 92.48 ± 14.9 96.29 ± 12.7 98.19 ± 12.8 NS
ABC (fear of falling) scale 68.3 ± 12.6 69.7 ± 16.0 65.7 ± 17.8 NS
STAI (Spielberger Anxiety
Inventory)
37.5 ± 7.6 34.3 ± 8.1 38.5 ± 10 F(7,792) = 0.545;
p = 0.006
Geriatric Depression Scale 9.4 ± 5.7 9.07 ± 5.3 10.26 ± 5.8 NS
Timed Up and Go test (s) 14.1 ± 3.8 13.1 ± 2.4 13.5 ± 2.5 F(4,863) = 0.448;
p = 0.028
Gait speed (m/s) 0.86 ± 0.8 0.90 ± 0.1 0.90 ± 0.2 NS
Stride-time variability (%) 3.65 ± 1.3 3.29 ± 1.0 3.36 ± 1.3 NS
MMSE Mini-Mental State Examination, NS not signiﬁcant, ABC Activities-speciﬁc Balance Conﬁdence scale, STAI State-Trait Anxiety
Inventory
a F indicates variance analysis of repeated measurements
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